Australian listed biotechnology company Prescient Therapeutics (ASX: PTX) today updated the market on progress on one of its personalised cancer therapy drugs, PTX-100. The results of the Phase 1b study means that PTX-100 can now move to the next level dose with two out of three patients from the first cohort showing stable or improved disease.

Principal Investigator of the PTX-100 trial, Professor H. Miles Prince AM, said, “We are encouraged by the good safety results to date and excited to proceed to the third cohort of this important cancer study.”

This Friday at 11am, in a special live event, CEO Steven Yatomi-Clarke will outline the exciting OmniCAR platform and update on PTX’s drug trials as well as its acceptance by the Doherty Institute of two of its assets for COVID-19 antiviral trials. Click here to book your spot.

PTX’s foundational assets, PTX-100 and PTX-200 both have significant addressable markets, and should they continue to progress they could present shareholders with considerable value.

In the past few months PTX has generated excitement with multiple announcements to the market that, in addition to its PTX-100 and PTX-200 programmes, the company is now the only Australian listed stock pursuing the hottest ticket in oncology: a revolutionary treatment called CAR T-cell therapy.

CAR-T, already a burgeoning multi-billion dollar industry, has transformed the way certain blood cancers are treated with stunning success. Johnson & Johnson recently released results showing 100% overall response rate from its CAR-T trial in multiple myeloma.

Prescient has exposure to this exciting CAR-T field with two new initiatives:  Cell Therapy Enhancements (CTE), and a next-gen CAR-T platform called OmniCAR.

Regarding CTE, PTX is working with Carina Biotech and Adelaide University on cell therapy enhancements that it says allow PTX’s wholly owned IP to be used globally by CAR-T providers through an “Intel Inside” business model.  

The OmniCAR platform was announced in late May, with technology exclusively licensed from University of Pennsylvania, the pioneers and world leaders in CAR-T, as well as Oxford University.  OmniCAR is a unique platform enabling creation of next generation CAR-T therapies that aims to massively expand the number of cancers that can be treated by CAR-T and improve the safety, control and efficacy of existing CAR-T treatments.   

PTX through innovative work into cell therapy enhancements and with the keys to what many believe is the best next generation CAR-T platform has brilliantly and strategically positioned itself in poll position and helps to shift the conversation around cancer from “treat” to “cure”.

PTX is currently raising $6.5m via a SPP, closing on the 17th of August at 5pm AEST. To participate in the SPP, eligible Shareholders can request an electronic version of their personal application forms here. 

This Friday at 11am, in a special live event, CEO Steven Yatomi-Clarke will outline the exciting OmniCAR platform and update on PTX’s drug trials as well as its acceptance by the Doherty Institute of two of its assets for COVID-19 antiviral trials. Click here to book your spot.

Reach Markets are the advisors assisting with the management of this offer and may receive fees depending on whether an offer is taken up by investors. Reach Markets have been engaged by PTX to help manage their investor communications.

Any advice contained in the presentation is general only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you.